![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Beijing
  86 (10) 6268 0518
86 (10) 6268 0106
zhang@ipfaith.com
Ms. Zhang is one of the founding partners of IPfaith Partners. She concentrates her practice on patent drafting, prosecution, re-examination, invalidation, patent infringement litigation, patent administrative litigation, and other IP-related consulting services.
Before joining IPfaith Partners, Ms. Zhang is a senior patent attorney at a leading intellectual property law firm in China. Ms. Zhang is very knowledgeable of the Chinese Patent Laws and Regulations, and has a tremendous rich experience in Chinese patent practice. She has helped clients including many famous multi-national corporations (MNC) and start-up enterprises prosecute hundreds of patent applications before the Chinese Patent Office, and has also handled a number of re-examination and invalidation cases before the Patent Re-examination Board.
Ms. Zhang had more than 12 years intellectual property protection experience in a wide range of technologies including biomedical, immunology, microbiology, pharmacy, medical devices, food, crops, materials, and broad chemistry discipline.
Ms. Zhang has handled patent prosecution in China for Wyeth, Kyowa Hakko Kirin (KHK), 3M, Janssen Alzheimer Immunotherapy, Baxter, Otsuka Pharmaceutical, Wm Wrigley Jr Company, L'OREAL, OSI Pharamaceuticals. She especially specialized in handling hard cases in the areas of immunology, crystal types of chemical drugs, crops, medical devices and instruments, diagnosis and treatment of diseases. For example, Ms. Zhang has helped two scientists returning from abroad obtain the critical granted patents in the fields of cell immunotherapy for tumors, and nano single-molecule genome analysis, respectively; she has helped a seed company of USA establish a patent portfolio in China, and she represented OSI Pharamaceuticals against two invalidations of the core patent of a selling drug "Tarceva (erlotinib)" for treating NSCLC in the Chinese market sold by Roche. In addition, Ms. Zhang not only has developed extensive experience in patent right protection for patented drug, original drug and generic drug, but also has in-depth exploration for the patent right protection strategy for tumor immunotherapy, including monoclonal antibody therapy and cell immunotherapy (CIK, DC-CIK, CAT-T and TCRT) in Chinese patent practice.
Ms. Zhang received a Bachelor's degree in Microbiology from China Agriculture University, and a Master's degree in Biomedicine from Peking Union Medical College, where she also began her first two-year occupation as a research assistant.
Ms. Ying ZHANG is a native Chinese speaker with full professional proficiency in English.